Fig. 2: Erlotinib upregulates a large number of RTK ligands and most were suppressed by concomitant prednisolone. | Nature Communications

Fig. 2: Erlotinib upregulates a large number of RTK ligands and most were suppressed by concomitant prednisolone.

From: Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

Fig. 2

a EGFRwt A549 cells were treated with 1 µM erlotinib with or without 10 µM prednisolone for 3 days. Total RNA was extracted and subjected to real-time PCR for detecting mRNA levels of multiple RTK ligands as listed. Real-time PCR were performed in three independent experiments, showing each value and mean ± SEM. The mean values, p-values, and q-values of multiple t-tests were summarized in Supplementary Table 1. The multiple comparison correction was corrected by two-stage step-up method of Benjamini, Krieger and Yekutieli. The desired false discovery rate (FDR) was set as 0.05. b, c HGF and NRG1 protein levels were validated by ELISA, under the same treatment condition as PCR. Three independent experiments show each result and mean ± SEM. **p < 0.01, ***p < 0.001 by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test. d–f Similar experiments were performed on EGFR mutant HCC827 cells, except that the dose of erlotinib was 100 nM. The statistical analysis above was performed on Graphpad Prism 9.0.0. Source data are provided as a Source Data file. p = 3E−7,0.001;0.0005,4E−4.

Back to article page